Statins in coronary artery bypass grafting surgery: Lipid lowering and beyond

Expert Review of Cardiovascular Therapy

Volumn 10, Issue 1, 2012, Pages 5-8

  Margaritis, Marios ^a   Antoniades, Charalambos ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

atrial fibrillation; coronary artery bypass grafting; endothelium; eNOS; NADPH oxidase; statins; superoxide

Indexed keywords

ATORVASTATIN; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN;

ACUTE CORONARY SYNDROME; CARDIOVASCULAR RISK; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY BYPASS GRAFT; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; GRAFT FAILURE; HUMAN; LONG TERM CARE; NONHUMAN; REVIEW; RISK REDUCTION;

ANIMALS; CARDIOVASCULAR DISEASES; CORONARY ARTERY BYPASS; GRAFT SURVIVAL; HEART; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPIDS; PERIOPERATIVE CARE;

EID: 83755172705     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/erc.11.174     Document Type: Review

References (25)

1. Hayward RA, Krumholz HM, Zulman DM, Timbie JW, Vijan S. Optimizing statin treatment for primary prevention of coronary artery disease. Ann. Int. Med. 152(2), 69-77 (2010).
2. Afilalo J, Duque G, Steele R, Jukema JW, De Craen AJ, Eisenberg MJ. Statins for secondary prevention in elderly patients: a hierarchical bayesian meta-analysis. J. Am. Coll. Cardiol. 51(1), 37-45 (2008).
3. Zeymer U, Junger C, Zahn R et al. Effects of a secondary prevention combination therapy with an aspirin, an ACE inhibitor and a statin on 1-year mortality of patients with acute myocardial infarction treated with a beta-blocker. Support for a polypill approach. Curr. Med. Res. Opin. 27(8), 1563-1570 (2011).
4. Pearson TA, Blair SN, Daniels SR et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update: consensus panel guide to Comprehensive Risk Reduction for Adult Patients Without Coronary or Other Atherosclerotic Vascular Diseases. American Heart Association Science Advisory and Coordinating Committee. Circulation 106(3), 388-391 (2002). (Pubitemid 34778969)
5. Anderson JL, Adams CD, Antman EM et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non ST-Elevation Myocardial Infarction): developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine. Circulation 116(7), e148-e304 (2007).
6. Eagle KA, Guyton RA, Davidoff R et al. ACC/AHA 2004 guideline update for coronary artery bypass graft surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Update the 1999 Guidelines for Coronary Artery Bypass Graft Surgery). Circulation 110(14), e340-e437 (2004).
7. Kulik A, Brookhart MA, Levin R, Ruel M, Solomon DH, Choudhry NK. Impact of statin use on outcomes after coronary artery bypass graft surgery. Circulation 118(18), 1785-1792 (2008).
8. Winchester DE, Wen X, Xie L, Bavry AA. Evidence of pre-procedural statin therapy a meta-analysis of randomized trials. J. Am. Coll. Cardiol. 56(14), 1099-1109 (2010).
9. No authors listed. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. The Post Coronary Artery Bypass Graft Trial Investigators. N. Engl. J. Med. 336(3), 153-162 (1997).
10. Shah SJ, Waters DD, Barter P et al. Intensive lipid-lowering with atorvastatin for secondary prevention in patients after coronary artery bypass surgery. J. Am. Coll. Cardiol. 51(20), 1938-1943 (2008). (Pubitemid 351636440)
11. Domanski M, Tian X, Fleg J et al. Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (post CABG) trial. Am. J. Cardiol. 102(8), 1023-1027 (2008).
12. Landmesser U, Bahlmann F, Mueller M et al. Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 111(18), 2356-2363 (2005). (Pubitemid 40647072)
13. Zhou Q, Liao JK. Statins and cardiovascular diseases: from cholesterol lowering to pleiotropy. Curr. Pharmaceut. Des. 15(5), 467-478 (2009).
14. Antoniades C, Bakogiannis C, Leeson P et al. Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 124(3), 335-345 (2011).
15. Antoniades C, Bakogiannis C, Tousoulis D et al. Preoperative atorvastatin treatment in CABG patients rapidly improves vein graft redox state by inhibition of Rac1 and NADPH-oxidase activity. Circulation 122(11 Suppl.), S66-S73 (2010).
16. Veillard NR, Braunersreuther V, Arnaud C et al. Simvastatin modulates chemokine and chemokine receptor expression by geranylgeranyl isoprenoid pathway in human endothelial cells and macrophages. Atherosclerosis 188(1), 51-58 (2006). (Pubitemid 44142533)
17. Ortego M, Bustos C, Hernandez-Presa MA et al. Atorvastatin reduces NF-kB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells. Atherosclerosis 147(2), 253-261 (1999). (Pubitemid 29512257)
18. Yang Z, Kozai T, Van Der Loo B et al. HMG-CoA reductase inhibition improves endothelial cell function and inhibits smooth muscle cell proliferation in human saphenous veins. J. Am. Coll.Cardiol. 36(5), 1691-1697 (2000).
19. Obi C, Wysokinski W, Karnicki K, Owen WG, Mcbane RD 2nd. Inhibition of platelet-rich arterial thrombus in vivo: acute antithrombotic effect of intravenous HMG-CoA reductase therapy. Arterioscl. Thromb. Vasc. Biol. 29(9), 1271-1276 (2009).
20. Puccetti L, Santilli F, Pasqui AL et al. Effects of atorvastatin and rosuvastatin on thromboxane-dependent platelet activation and oxidative stress in hypercholesterolemia. Atherosclerosis 214(1), 122-128 (2011).
21. Porter KE, Turner NA. Statins and myocardial remodelling: cell and molecular pathways. Expert Rev. Mol. Med. 13, e22 (2011).
22. Patti G, Chello M, Candura D et al. Randomized trial of atorvastatin for reduction of postoperative atrial fibrillation in patients undergoing cardiac surgery: results of the ARMYDA-3 (Atorvastatin for Reduction of Myocardial Dysrhythmia After Cardiac Surgery) study. Circulation 114(14), 1455-1461 (2006). (Pubitemid 44526999)
23. Xu Q, Guan YQ, Zhang D, Su GH. The effects of statin on atrial fibrillation: a meta-analysis of published data from randomized controlled trials. Curr. Med. Res. Opin. 27(9), 1771-1779 (2011).
24. Kim YM, Guzik TJ, Zhang YH et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ. Res. 97(7), 629-636 (2005). (Pubitemid 41416331)
25. Antoniades C, Demosthenous M, Reilly S et al. Myocardial redox state predicts in-hospital clinical outcome after cardiac surgery: effects of short-term preoperative statin treatment. J. Am. Coll. Cardiol. (2011) (In Press).